@FierceBiotech: Rigel shares slide after another drug flops in PhII asthma study. Story | Follow @FierceBiotech
@JohnCFierce: Two years ago Rigel was celebrating when Pfizer turned over R343. Now enthusiasm likely dimmed as top 2 drugs are under a dark cloud. | Follow @JohnCFierce
@EmilyMFierce: High copper levels implicated in Alzheimer's disease. Story | Follow @EmilyMFierce
> David Blech, once known in some circles as the "King of Biotech," has reached a settlement deal with the SEC regarding charges of market manipulation of shares of Pluristem Therapeutics ($PSTI) and Intellect Neurosciences. Story
> Sanofi ($SNY) is touting new data on patients 65 and older for its high-dose version of Fluzone. Story
@FierceMedDev: Sign up for our new publication, FierceDiagnostics, launching with its first weekly newsletter this Wednesday. Sign up | Follow @FierceMedDev
@DamianFierce: CROs are dishing out more and more bonuses to quell sky-high turnover rates, according to a study. Report | Follow @DamianFierce
@MarkHFierce: Thermo Fisher is rolling out a major scholarship program for science/math students at elite universities. Smart. Release | Follow @MarkHFierce
@MichaelGFierce: Zimmer lands FDA clearance for 3-D surgical system. Article | Follow @MichaelGFierce
> Medtronic fails to stop patient's Infuse lawsuit. News
> Investment bank launches healthcare-focused crowdfunding option. Item
Pharma News
@FiercePharma: Japan's budget-minded PM wants to open universal health system to more add-on treatments. Could boost cancer meds. Article | Follow @FiercePharma
@EricPFierce: Australia to track Yervoy patients to see if it's worth the $110K price. More | Follow @EricPFierce
@CarlyHFierce: Ex-Novartis chair Vasella considers his results worth the once-approved $78M payout--will make $5.2M instead. Story | Follow @CarlyHFierce
> Australia to track Yervoy patients to see if it's worth the $110K price. News
> Sanofi eyes superiority claim for Fluzone High-Dose after trial boost. More
CRO News
> U.K. outfit bets on early-phase outsourcing. News
> CRO Psi jumps into India. More
> Vince & Associates eyes gastro trials with expansion. Article
> Study: CROs dishing out bonuses to halt high turnover. Story
> Icon dives into adaptive trial monitoring. News
Biotech IT News
> Capgemini taps Amazon cloud for Big Data analytics. Story
> Harvard-MIT collaboration adds Lego-like genome analysis tool. Article
> Google bolsters security of cloud data storage service. More
> FDA pilot project ups benefits of IT supply chain investments. News
> EMA to start accepting digital signatures next month. Story
And Finally… Investigators at Johns Hopkins say they have identified a new target for drug developers focused on Parkinson's disease. "Not only were we able to identify the mechanism that could cause progressive cell death in both inherited and non-inherited forms of Parkinson's, we found there were already compounds in existence that can cross into the brain and block this from happening," says Johns Hopkins' Valina Dawson. Release